Lithium and Renal Impairment: A Review on a Still Hot Topic

Abstract

Introduction Lithium is established as an effective treatment of mania, of depression in bipolar and unipolar disorder, and in maintenance treatment of these disorders. However, due to the necessity of monitoring and concerns about irreversible adverse effects, in particular renal impairment, after long-term use, lithium might be underutilized.

Methods This study reviewed 6 large observational studies addressing the risk of impaired renal function associated with lithium treatment and methodological issues impacting interpretation of results.

Results An increased risk of renal impairment associated with lithium treatment is suggested. This increased risk may, at least partly, be a result of surveillance bias. Additionally, the earliest studies pointed toward an increased risk of end-stage renal disease associated with lithium treatment, whereas the later and methodologically most sound studies do not.

Discussion The improved renal outcome found in the more recent lithium studies may be a result of improved monitoring and focus on recommended serum levels (preferentially 0.6–0.8 mmol/L) as compared to poorer renal outcome in studies with patients treated in the 1960s to 1980s.

Key words

lithium - renal impairment - epidemiology - adverse events

• References

• 1 Shorter E. The history of lithium therapy. Bipolar Disord. 2009; 11: 4-9
• 2 Licht RW. Lithium: Still a major option in the management of bipolar disorder. CNS Neurosci Ther 2012; 18: 219-226
• 3 Bschor T. Lithium in the treatment of major depressive disorder. Drugs 2014; 74: 855-862
• 4 Smith KA, Cipriani A. Lithium and suicide in mood disorders: Updated meta-review of the scientific literature. Bipolar Disord. 2017; 19: 575-586
• 5 Abou-Saleh MT, Müller-Oerlinghausen B, Coppen AJ. Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. Int J. Bipolar Disord. 2017; 5: 11
• 6 Kessing LV, Gerds TA, Knudsen NN. et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry 2017; 74: 1005-1010
• 7 Gitlin M. Lithium side effects and toxicity: Prevalence and management strategies. Int J. Bipolar Disord. 2016; 4: 27
• 8 Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord. 2016; 18: 174-182
• 9 Gong R, Wang P, Dworkin L. What we need to know about the effect of lithium on the kidney. Am J Physiol Ren Physiol 2016; 311: F1168-F1171
• 10 Hestbech J, Hansen HE, Amdisen A. et al. Chronic renal lesions following long-term treatment with lithium. Kidney Int. 1977; 12: 205-213
• 11 Aurell M, Svalander C, Wallin L. et al. Renal function and biopsy findings in patients on long-term lithium treatment. Kidney Int. 1981; 20: 663-670
• 12 Bendz H, Aurell M, Balldin J. et al. Kidney damage in long-term lithium patients: A cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant. 1994; 9: 1250-1254
• 13 Bendz H, Sjödin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant. 1996; 11: 457-460
• 14 Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. Eur Psychiatry. 2001; 16: 199-206
• 15 Bendz H, Schön S, Attman PO. et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010; 77: 219-224
• 16 Aiff H, Attman PO, Aurell M. et al. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014; 24: 540-544
• 17 Close H, Reilly J, Mason JM. et al. Renal failure in lithium-treated bipolar disorder: A retrospective cohort study. PLoS One 2014; 9: e90169
• 18 Shine B, McKnight RF, Leaver L. et al Long-term effects of lithium on renal, thyroid, and parathyroid function: A retrospective analysis of laboratory data. Lancet 2015; 386: 461-468
• 19 Kessing LV, Gerds TA, Feldt-Rasmussen B. et al. Use of lithium and anticonvulsants and the rate of chronic kidney disease: A nationwide population-based study. JAMA Psychiatry 2015; 1-10
• 20 Hayes JF, Marston L, Walters K. et al. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: A population-based cohort study. PLoS Med. 2016; 13: e1002058
• 21 Boyko EJ. Observational research – opportunities and limitations. J Diabetes Complications 2013; 27: 642-648
• 22 McKnight RF, Adida M, Budge K. et al. Lithium toxicity profile: A systematic review and meta-analysis. Lancet 2012; 379: 721-728
• 23 Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA 2011; 305: 2462-2463
• 24 Forty L, Ulanova A, Jones L. et al. Comorbid medical illness in bipolar disorder. Br J Psychiatry. 2014; 205: 465-472
• 25 Nielsen RE, Licht RW. Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder. Evid Based Med 2017; 22: 74-75
• 26 Kessing LV, Feldt-Rasmussen B, Andersen PK. et al. Continuation of lithium after a diagnosis of chronic kidney disease. Acta Psychiatr Scand. 2017; 136: 615-622
• 27 Kessing LV. Treatment options in bipolar disorder: lessons from population-based registers with focus on lithium. Curr Treat Options Psychiatry 2015; 2: 218-228
• 28 Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc 2016; 9: 211-217
• 29 Goodwin GM. The safety of lithium. JAMA Psychiatry 2015; 72: 1167-1169
• 30 Aiff H, Attman PO, Aurell M. et al. The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol. 2014; 28: 151-154
• 31 Clos S, Rauchhaus P, Severn A. et al Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: A population-based cohort study. The Lancet Psychiatry 2015; 2: 1075-1083